PubRank

D A Cooper

Author PubWeight™ 318.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 8.88
2 Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 7.08
3 Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000 6.49
4 Adverse effects of antiretroviral therapy. Lancet 2000 4.84
5 Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985 4.83
6 Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009 4.38
7 The 2010 Royal Australasian College of Physicians' policy statement 'Circumcision of infant males' is not evidence based. Intern Med J 2012 4.15
8 A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995 3.89
9 Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996 3.48
10 Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet 1985 3.33
11 Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999 3.28
12 Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998 3.22
13 Primary HIV infection: host responses and intervention strategies. AIDS 1991 2.80
14 Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992 2.65
15 Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992 2.60
16 Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996 2.44
17 Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998 2.43
18 A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000 2.36
19 Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017) AIDS 1994 2.23
20 CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996 2.23
21 Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013 2.23
22 Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes. Science 1983 2.21
23 Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001 2.17
24 HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 1998 2.16
25 HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001 2.14
26 Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 1992 2.08
27 High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001 2.03
28 Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men. Med J Aust 1989 2.02
29 Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis 2000 1.91
30 Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998 1.88
31 CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991 1.85
32 The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995 1.82
33 Acquired immunodeficiency without evidence of HIV infection: national retrospective survey. BMJ 1994 1.78
34 Ribavirin: a role in HIV infection? J Acquir Immune Defic Syndr 1990 1.74
35 Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999 1.70
36 The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991 1.69
37 Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise. Blood 1993 1.54
38 Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. AIDS 1996 1.46
39 The neurological features of early and 'latent' human immunodeficiency virus infection. Aust N Z J Med 1989 1.42
40 Syringe HIV seroprevalence and behavioural and demographic characteristics of intravenous drug users in Sydney, Australia, 1987. AIDS 1988 1.41
41 Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis 1998 1.41
42 Bile acid malabsorption in HIV infected patients with chronic diarrhoea. Aust N Z J Med 1996 1.40
43 HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004 1.39
44 Survival of patients with the acquired immunodeficiency syndrome in Australia. Med J Aust 1989 1.39
45 If it's the virus, why aren't we measuring it? Med J Aust 1995 1.38
46 Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum. Lancet 1987 1.37
47 Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology 1989 1.35
48 Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol 1994 1.34
49 HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003 1.34
50 Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997 1.33
51 Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Am J Clin Nutr 2001 1.32
52 Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997 1.30
53 Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med 2007 1.29
54 Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998 1.29
55 Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS 1997 1.27
56 Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis 1990 1.26
57 HIV infection of rectal mucosa. Lancet 1988 1.22
58 A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 2000 1.21
59 B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000 1.20
60 Serum concentrations of retinol, alpha-tocopherol and the carotenoids are influenced by diet, race and obesity in a sample of healthy adolescents. J Nutr 2001 1.20
61 Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998 1.18
62 Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006 1.18
63 Human cytotoxic T cell clones directed at autologous virus-transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteins. J Immunol 1983 1.18
64 Antibody response to human immunodeficiency virus after primary infection. J Infect Dis 1987 1.17
65 Behcet's syndrome: clinical, immunological and therapeutic evaluation of 17 patients. Aust N Z J Med 1974 1.17
66 Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006 1.17
67 Quinolinic acid production is related to macrophage tropic isolates of HIV-1. J Neurovirol 1995 1.17
68 Gastrointestinal viral infections in homosexual men who were symptomatic and seropositive for human immunodeficiency virus. J Infect Dis 1988 1.15
69 Immunoregulatory human T lymphocytes triggered as a consequence of viral infection: clonal analysis of helper, suppressor inducer and suppressor effector cell populations. J Immunol 1983 1.14
70 Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000 1.13
71 Cigarettes, cough, and cancer of the lung. JAMA 1966 1.12
72 Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 1994 1.12
73 Demographic, dietary and lifestyle factors differentially explain variability in serum carotenoids and fat-soluble vitamins: baseline results from the sentinel site of the Olestra Post-Marketing Surveillance Study. J Nutr 1999 1.12
74 Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Curr Opin Microbiol 2000 1.11
75 HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001 1.10
76 Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection. J Infect Dis 2001 1.10
77 Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. J Infect Dis 1998 1.09
78 HIV seroconversion illness. Med J Aust 1993 1.09
79 Primary human immunodeficiency virus infection. Clinical and serologic aspects. Infect Dis Clin North Am 1988 1.09
80 Growth rate in the detection and prognosis of bronchogenic carcinoma. JAMA 1966 1.09
81 A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. AIDS 1996 1.08
82 A proteinase from human erythrocyte membranes. Biochim Biophys Acta 1970 1.07
83 Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993 1.07
84 Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis 1996 1.05
85 Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood 1991 1.04
86 Culture and properties of cells derived from Kaposi sarcoma. J Immunol 1991 1.04
87 Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000 1.04
88 Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Med 2007 1.04
89 Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000 1.03
90 Scytalidium dimidiatum and Lecythophora hoffmannii: unusual causes of fungal infections in a patient with AIDS. J Clin Microbiol 1997 1.03
91 Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. AIDS Res Hum Retroviruses 1999 1.03
92 Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis 1994 1.02
93 Macular pigment optical density in a midwestern sample. Ophthalmology 2001 1.01
94 Helicobacter pylori-associated gastritis is rare in AIDS: antibiotic effect or a consequence of immunodeficiency? Am J Gastroenterol 1991 1.01
95 Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. AIDS 1995 1.01
96 A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther 2008 1.01
97 Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis 2000 1.01
98 Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res Hum Retroviruses 2001 1.00
99 Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. J Infect Dis 1996 1.00
100 The Philadelphia pulmonary neoplasm research project: basic risk factors of lung cancer in older men. Am J Epidemiol 1972 1.00
101 T and B cell populations in blood and lymph node in lymphoproliferative disease. Br J Cancer 1975 1.00
102 Breast-feeding during primary maternal human immunodeficiency virus infection and risk of transmission from mother to infant. J Infect Dis 1993 0.99
103 HIV infection associated with symptoms indistinguishable from functional psychosis. Br J Psychiatry 1988 0.98
104 Current clinical experience with nevirapine for HIV infection. Adv Exp Med Biol 1996 0.98
105 The Philadelphia pulmonary neoplasm research project. Survival factors in bronchogenic carcinoma. JAMA 1971 0.97
106 Corticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. Clin Exp Immunol 1979 0.97
107 Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. HIV Med 2011 0.97
108 Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999 0.96
109 Severe clinical manifestations of primary HIV infection. AIDS 1989 0.96
110 Increased expression of interferon-gamma in hyperplastic lymph nodes from HIV-infected patients. Clin Exp Immunol 1993 0.96
111 Sexual practices and condom usage in a cohort of homosexual men in relation to human immunodeficiency virus status. Med J Aust 1989 0.96
112 Abnormal fat distribution and use of protease inhibitors. Lancet 1998 0.96
113 Seroimmunology of AIDS retrovirus infection. I. Use of immunofluorescence assay to confirm sera with ELISA reactivity. Pathology 1986 0.96
114 Operative mortality and 5-year survival rates in men with bronchogenic carcinoma. Ann Intern Med 1969 0.95
115 Anaerobic biodegradation of cyanide under methanogenic conditions. Appl Environ Microbiol 1991 0.95
116 The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. HIV Med 2005 0.95
117 In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993 0.95
118 Fertility and reproductive choice in women with HIV-1 infection. AIDS 1997 0.95
119 The role of surgery in the cure of lung cancer. Arch Intern Med 1967 0.94
120 Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group. AIDS Res Hum Retroviruses 1998 0.94
121 Primary carcinoma of the lung in nonsmokers. Arch Environ Health 1968 0.94
122 Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. J Acquir Immune Defic Syndr 1999 0.94
123 Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients. AIDS Res Hum Retroviruses 1992 0.93
124 Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrob Agents Chemother 2001 0.93
125 CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia. J Infect Dis 1999 0.92
126 Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998 0.91
127 Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes. AIDS Res Hum Retroviruses 1999 0.91
128 Identification of HIV-1 in semen following primary HIV-1 infection. AIDS 1992 0.91
129 Patients infected with human immunodeficiency virus type 1 have low levels of virus in saliva even in the presence of periodontal disease. J Infect Dis 1993 0.91
130 Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials 2003 0.90
131 Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive? Clin Infect Dis 1997 0.90
132 The histopathology of bronchogenic carcinoma and its relation to growth rate, metastasis, and prognosis. Cancer 1970 0.89
133 High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997 0.89
134 Therapeutic strategies for HIV infection--time to think hard. N Engl J Med 1998 0.89
135 The effect of acute and prolonged administration of prednisolone and ACTH on lymphocyte subpopulations. Clin Exp Immunol 1977 0.89
136 Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis. AIDS 1991 0.89
137 Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. AIDS Res Hum Retroviruses 2001 0.88
138 Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group. J Acquir Immune Defic Syndr 1999 0.88
139 Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin Rev 1996 0.88
140 Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993 0.88
141 Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000 0.88
142 Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect 1999 0.87
143 Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects. Clin Exp Immunol 1999 0.87
144 Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling. AIDS Res Hum Retroviruses 2001 0.87
145 Allergic manifestations of human immunodeficiency virus (HIV) infection. J Clin Immunol 1991 0.87
146 The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust N Z J Med 1988 0.87
147 Assessing adherence in Thai patients taking combination antiretroviral therapy. Int J STD AIDS 2012 0.87
148 The costs of hospital-based medical care for patients with the acquired immunodeficiency syndrome. Med J Aust 1987 0.87
149 Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. AIDS 2000 0.86
150 Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine. Patient Educ Couns 1994 0.86
151 Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group. AIDS 1994 0.86
152 Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI). Clin Exp Immunol 1992 0.86
153 Behind the identification of China White. Anal Chem 1981 0.86
154 Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. AIDS 1996 0.86
155 Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens. HIV Med 2002 0.86
156 Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol 1998 0.85
157 Herpes zoster and the stage and prognosis of HIV-1 infection. Genitourin Med 1997 0.85
158 Prevalence of maternal HIV infection based on anonymous testing of neonates, Sydney 1989. Med J Aust 1990 0.85
159 Risks of human immunodeficiency and hepatitis B viral infections in intravenous drug abusers. Med J Aust 1988 0.85
160 The gastrointestinal manifestations of AIDS. Aust N Z J Med 1990 0.85
161 Glucocorticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. Clin Exp Immunol 1981 0.84
162 Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1. Clin Exp Immunol 1992 0.84
163 HIV-associated lipodystrophy. HIV Med 2001 0.84
164 Patterns of multiple-drug hypersensitivities in HIV-infected patients. AIDS 1993 0.84
165 Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. The Australian Zidovudine Study Group. AIDS 1990 0.84
166 Biosynthesis of immunoglobulin in human immunoproliferative diseases. I. Kinetics of synthesis and secretion of immunoglobulin and protein by bone marrow cells in myeloma. J Immunol 1978 0.84
167 The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Curr Opin Infect Dis 2001 0.83
168 Kaposi's sarcoma-associated herpesvirus: a sexually transmissible infection? J Acquir Immune Defic Syndr Hum Retrovirol 1999 0.83
169 Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 2001 0.83
170 Definition of two distinct types of AIDS-associated non-Hodgkin lymphoma. Br J Haematol 1990 0.83
171 Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response. AIDS 1993 0.83
172 A model of primary HIV-1 infection. Math Biosci 1998 0.82
173 Sexual dysfunction in advanced HIV disease. AIDS Care 1994 0.82
174 Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men. J Acquir Immune Defic Syndr 1993 0.82
175 False-negative ELISA result for HIV antibody due to an apparent prozone phenomenon. Med J Aust 1987 0.82
176 HIV risk factors and seroprevalence in surgical patients. Med J Aust 1993 0.82
177 Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res Hum Retroviruses 1997 0.82
178 Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 1998 0.82
179 Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. Hum Vaccin 2007 0.82
180 Prevalence of antibodies to Epstein-Barr virus nuclear antigen 2B in persons infected with the human immunodeficiency virus. J Infect Dis 1988 0.82
181 The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 2007 0.82
182 Postoperative malignant hyperthermia: a case report. Can Anaesth Soc J 1971 0.82
183 Chronic colitis associated with human immunodeficiency virus infection. Med J Aust 1992 0.81
184 A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS 2000 0.81
185 Survival of men with peripheral lung cancer in relation to histologic characteristics and growth rate. Am Rev Respir Dis 1968 0.81
186 Determination and in-depth chromatographic analyses of alkaloids in South American and greenhouse-cultivated coca leaves. J Chromatogr A 1994 0.80
187 Anxiety, depression and HIV related symptomatology across the spectrum of HIV disease. Aust N Z J Psychiatry 1992 0.80
188 Differences in time from HIV seroconversion to CD4+ lymphocyte end-points and AIDS in cohorts of homosexual men. AIDS 1993 0.80
189 Summary of the III International Consensus Symposium on Combined Antiviral Therapy. Antiviral Res 1998 0.80
190 The Philadelphia Pulmonary Neoplasm Research Project. Med Clin North Am 1970 0.80
191 Hepatitis C virus core mutations reduce the sensitivity of a fluorescence enzyme immunoassay. J Clin Microbiol 2000 0.80
192 Separation of retinyl esters by non-aqueous reversed-phase high-performance liquid chromatography. J Chromatogr 1986 0.80
193 Latent reservoirs of HIV infection: flushing with IL-2? Nat Med 1999 0.80
194 Effect of zidovudine on survival of patients with AIDS in Australia. Med J Aust 1990 0.80
195 Characterization of the phenotypic and lymphokine profile associated with strong CD8+ anti-HIV-1 suppressor activity (CASA). Clin Exp Immunol 2002 0.80
196 Risk of Kaposi's sarcoma and oroanal sexual contact. Am J Epidemiol 1997 0.80
197 Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects. Hum Vaccin 2005 0.80
198 Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1997 0.80
199 Antiretroviral treatment: state of the art and future directions. AIDS 1991 0.80
200 Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor. AIDS 1997 0.80
201 Glucocorticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. III. Common variable immunodeficiency. Clin Exp Immunol 1981 0.80
202 HIV protease inhibitors. AIDS 1996 0.80
203 A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. AIDS 2000 0.80
204 Sequence analyses of the reverse transcriptase region of HIV type 1 isolates from Sydney, Australia. AIDS Res Hum Retroviruses 1996 0.79
205 Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. HIV Med 2009 0.79
206 Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile? Sex Transm Infect 2006 0.79
207 No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010 0.79
208 Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators. AIDS 1998 0.79
209 Pneumoconiosis among workers in an antimony industry. Am J Roentgenol Radium Ther Nucl Med 1968 0.79
210 Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 2000 0.79
211 Chronic cough in patients with HIV infection. Scand J Infect Dis 1998 0.79
212 Prophylaxis of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr 1993 0.79
213 Progression of periodontal disease in HIV seropositive patients. J Periodontol 1993 0.79
214 Cryptosporidiosis in the acquired immune deficiency syndrome. Pathology 1984 0.78
215 Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1. Immunol Cell Biol 1995 0.78
216 Characterization of the V3 region of HIV-1 isolates from Sydney, Australia. AIDS Res Hum Retroviruses 1995 0.78
217 Changes in neuropsychological performance of AIDS-related complex patients who progress to AIDS. AIDS 1992 0.78
218 Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. HIV Med 2008 0.78
219 A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. J Acquir Immune Defic Syndr 2001 0.78
220 AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment. AIDS 1999 0.78
221 A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma. Aust N Z J Med 1998 0.78
222 Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med 2001 0.78
223 Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV. Med J Aust 1996 0.78
224 Second pulmonary neoplasms among long-term survivors of lung cancer. Am Rev Respir Dis 1965 0.78
225 Long-term prognosis following zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. J Infect Dis 1999 0.78
226 Esophageal ulceration induced by zidovudine. Ann Intern Med 1990 0.78
227 Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy? J Antimicrob Chemother 1999 0.78
228 Lymphoproliferative disease with IgM lambda monoclonal protein and autoimmune hemolytic anemia. A report of four cases and a review of the literature. Am J Med 1978 0.78
229 Ovarian, hormonal, and reproductive events associated with synchronization of ovulation and timed appointment breeding of Bos indicus-influenced cattle using intravaginal progesterone, gonadotropin-releasing hormone, and prostaglandin F2alpha. J Anim Sci 2007 0.77
230 Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997 0.77
231 Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial). HIV Med 2011 0.77
232 Epstein-Barr virus and HIV play no direct role in persistent generalized lymphadenopathy syndrome. Clin Exp Immunol 1992 0.77
233 The role of Epstein-Barr virus subtypes in human immunodeficiency virus-associated lymphoma. Leuk Lymphoma 1993 0.77
234 Olestra ingestion and retinyl palmitate absorption in humans. J Nutr 1997 0.77
235 A role for olestra in body weight management. Obes Rev 2002 0.77
236 Zidovudine in the management of primary HIV-1 infection. AIDS 1991 0.77
237 Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. HIV Med 2008 0.77
238 Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine. J Infect Dis 1996 0.77
239 Determination of fentanyl and related compounds by capillary gas chromatography with electron capture detection. Anal Chem 1986 0.77
240 Malignant melanoma associated with human immunodeficiency virus infection in three homosexual men. J Am Acad Dermatol 1989 0.77
241 Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney. AIDS 2000 0.77
242 Biosynthesis of immunoglobulin in human immunoproliferative diseases. II. Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with that calculated from clinical staging systems. Acta Haematol 1982 0.77
243 Factors contributing to the formation of experimentally-induced ovarian cysts in prepubertal gilts. Domest Anim Endocrinol 1993 0.77
244 Physical or temporal separation of olestra and vitamins A, E and D intake decreases the effect of olestra on the status of the vitamins in the pig. J Nutr 1997 0.77
245 Olestra affects serum concentrations of alpha-tocopherol and carotenoids but not vitamin D or vitamin K status in free-living subjects. J Nutr 1997 0.77
246 Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial. Int J Antimicrob Agents 1999 0.77
247 Late manifestations of HIV in Asia and the Pacific. AIDS 1994 0.76
248 Clinical trials in Asia. AIDS 1998 0.76
249 Primary structure of the V3 region of gp120 from sequential human immunodeficiency virus type 1 isolates obtained from patients from the time of seroconversion. J Infect Dis 1995 0.76
250 Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med 2005 0.76
251 Olestra ingestion and dietary fat absorption in humans. J Nutr 1997 0.76
252 Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS). J Allergy Clin Immunol 1993 0.76
253 Genital shedding of HIV after scheduled treatment interruption. Int J STD AIDS 2011 0.76
254 Neuropsychological investigation of patients with AIDS and ARC. J Acquir Immune Defic Syndr 1990 0.76
255 The survival of men with measurable proved lung cancer in relation to growth rate. Am J Roentgenol Radium Ther Nucl Med 1966 0.75
256 The European-Australian Collaborative Group Study 017 of zidovudine versus placebo. AIDS 1995 0.75
257 AIDS 1997. Clinical treatment: overview. AIDS 1997 0.75
258 Suppression of IgE synthesis in vitro by allogeneic T cells from atopic and non-atopic subjects. Clin Exp Immunol 1985 0.75
259 Epidemiology of acquired immunodeficiency syndrome in Australia . Med J Aust 1987 0.75
260 Drug companies have a duty to continue treatment. BMJ 1997 0.75
261 Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses 1999 0.75
262 Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV Med 2010 0.75
263 Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy. HIV Med 2010 0.75
264 Neurological manifestations of HIV-1 infection. AIDS 1991 0.75
265 Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994 0.75
266 Assay of liver retinyl ester hydrolase. Methods Enzymol 1990 0.75
267 Lung cancer and surgery. Ann Intern Med 1969 0.75
268 1H nuclear magnetic resonance of heroin's D ring. J Forensic Sci 1985 0.75
269 Current status of clinical trials in HIV disease in Australia. J Acquir Immune Defic Syndr 1993 0.75
270 Clinical and immunologic sequelae of AIDS retrovirus infection. Aust N Z J Med 1986 0.75
271 Change in zidovudine prescribing practices in Australia, 1991-1993. Aust N Z J Med 1995 0.75
272 Fifth International Conference on the acquired immunodeficiency syndrome. Med J Aust 1990 0.75
273 Treatment with human chorionic gonadotropin (hCG) for ovulation induction is associated with an immediate 17beta-estradiol decrease and a more rapid LH increase in mares. Anim Reprod Sci 2008 0.75
274 AIDS and prostitutes. Med J Aust 1986 0.75
275 Complete regression of locally-advanced breast cancer with chemotherapy. Med J Aust 1981 0.75
276 Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome. HIV Med 2008 0.75
277 Development of AIDS in a cohort of HIV-seropositive homosexual men in Australia. Med J Aust 1990 0.75
278 Augmentation of HIV-specific lymphoproliferation in HIV-infected individuals by TraT: a novel T-cell immunopotentiating agent. AIDS 1993 0.75
279 Attitudes to euthanasia and assisted suicide in a group of homosexual men with advanced HIV disease. J Acquir Immune Defic Syndr 1993 0.75
280 Substance use among HIV patients. Ir J Med Sci 2010 0.75
281 Inadvertent placement of advertisements. Med J Aust 1994 0.75
282 Bridging the divide: global inequities in access to HIV/AIDS therapy. Med J Aust 2002 0.75
283 Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs 1998 0.75
284 The surveillance definition of the acquired immunodeficiency syndrome and the clinical classification of infection with the human immunodeficiency virus type 1. Med J Aust 1988 0.75
285 The immunological basis of immediate hypersensitivity. Aust Fam Physician 1979 0.75
286 Update on reverse transcriptase inhibitors in HIV disease. Isr J Med Sci 1993 0.75
287 Illicit heroin manufacturing byproducts: capillary gas chromatographic determination and structural elucidation of narcotine- and norlaudanosine-related compounds. Anal Chem 1984 0.75
288 Temporal relationships of the LH surge and ovulation to echotexture and power Doppler signals of blood flow in the wall of the preovulatory follicle in heifers. Reprod Fertil Dev 2010 0.75
289 Monitoring immune function during immunosuppressive therapy. Aust N Z J Med 1976 0.75
290 An unusual red cell response to injury. Bibl Anat 1979 0.75
291 Determination of neutral manufacturing impurities in heroin by capillary gas chromatography with electron capture detection after reduction with lithium aluminum hydride and derivatization with heptafluorobutyric anhydride. Anal Chem 1986 0.75
292 Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection. Aust N Z J Med 1995 0.75
293 Sexual activity of HIV patients. Ir J Med Sci 2010 0.75
294 Analysis of manufacturing by-products and impurities in illicit cocaine via high-performance liquid chromatography and photodiode array detection. J Chromatogr 1987 0.75
295 Novel chlorinated tropanes derived from the treatment of cocaine with sodium hypochlorite. J Forensic Sci 1995 0.75
296 Requests for psychiatric consultation concerning 22 patients with AIDS and ARC. Aust N Z J Psychiatry 1987 0.75
297 John Blair Barnwell, M.D. Trans Am Clin Climatol Assoc 1968 0.75
298 Fourth International Conference on the acquired immunodeficiency syndrome. Med J Aust 1989 0.75
299 Voluntary HIV antibody testing among STD clinic patients: a pilot study. Med J Aust 1990 0.75
300 Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group. AIDS 1994 0.75
301 Pulmonary manifestations of the acquired immunodeficiency syndrome. Aust N Z J Med 1987 0.75
302 Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates. AIDS 2000 0.75
303 Contact tracing in the acquired immune deficiency syndrome (AIDS). Evidence for transmission of virus and disease by an asymptomatic carrier. Med J Aust 1984 0.75
304 The effect of purified alpha 1 antitrypsin on PWM driven IgG synthesis. J Clin Lab Immunol 1984 0.75
305 Changes in human erythrocyte membrane proteins during storage. Vox Sang 1971 0.75
306 Neuropsychological function in asymptomatic HIV-1 infection: methodological issues. J Clin Exp Neuropsychol 1994 0.75
307 World AIDS Day: what progress since last year? Med J Aust 1996 0.75
308 Antibodies to the human immunodeficiency virus in needles and syringes used by intravenous drug abusers. Med J Aust 1987 0.75
309 The application of capillary gas chromatography-electron capture detection in the comparative analyses of illicit cocaine samples. J Forensic Sci 1993 0.75
310 Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies. Antiviral Res 1997 0.75
311 [Anti-HIV treatment, today and in the near future]. Ned Tijdschr Geneeskd 1992 0.75
312 Predicting the course of AIDS in Australia. Med J Aust 1990 0.75
313 HIV positive: who do they tell? Int J STD AIDS 2009 0.75
314 HIV and AIDS. Gap between biology and reality in AIDS. Lancet 1999 0.75
315 Simple and choice reaction time in patients with human immunodeficiency virus infection. Ann Neurol 1989 0.75
316 Presynchronization with gonadotropin-releasing hormone increases the proportion of Bos indicus-influenced females ovulating at initiation of synchronization but fails to improve synchronized new follicular wave emergence or fixed-time artificial insemination conception rates using intravaginal progesterone, gonadotropin-releasing hormone, and prostaglandin F2alpha1. J Anim Sci 2010 0.75
317 Update on HIV infection. Aust Fam Physician 1991 0.75
318 Resolution of amyloidosis (AA type) complicating chronic ulcerative colitis. Gastroenterology 1988 0.75
319 A monoclonal antibody-based radioimmunoassay for the in vitro production of IgE by lymphocyte cultures. Int Arch Allergy Appl Immunol 1985 0.75
320 CD4+ lymphocytopenia in HIV-seronegative homosexual men. AIDS 1993 0.75
321 Memorial. Hubert Willows Hetherington, M.D. Trans Am Clin Climatol Assoc 1969 0.75
322 Capillary gas chromatographic-electron capture detection of coca-leaf-related impurities in illicit cocaine: 2,4-diphenylcyclobutane-1,3-dicarboxylic acids, 1,4-diphenylcyclobutane-2,3-dicarboxylic acids and their alkaloidal precursors, the truxillines. J Chromatogr 1987 0.75
323 Epidemic Kaposi's sarcoma and opportunistic infections. Med J Aust 1983 0.75
324 Sexual behavioural change in partners of homosexual men infected with human immunodeficiency virus. Med J Aust 1988 0.75
325 CD8+ T-cells from HIV-infected patients can either augment or abrogate HIV-specific lymphoproliferation. Clin Immunol Immunopathol 1992 0.75
326 IgA kappa multiple myeloma and lymphadenopathy syndrome associated with AIDS virus infection. Aust N Z J Med 1986 0.75
327 Immunoregulation in juvenile chronic arthritis. Int Arch Allergy Appl Immunol 1984 0.75
328 In-vitro synthesis of an anti-BI cold agglutinin complicating a case of lymphoma. Am J Clin Pathol 1979 0.75
329 Evaluation of vaginal electrical resistance as an indicator of follicular maturity and suitability for timed artificial insemination in beef cows subjected to a synchronization of ovulation protocol. Anim Reprod Sci 2007 0.75
330 The acquired immunodeficiency syndrome and tuberculosis. Med J Aust 1989 0.75
331 AIDS and related conditions. One year's experience in St. Vincent's Hospital, Sydney. Med J Aust 1984 0.75
332 The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex. AIDS 1992 0.75
333 Incidence of HIV infection in a cohort of homosexually active men. Aust N Z J Public Health 1997 0.75
334 Estimations of real-world N2O emissions from road vehicles by means of measurements in a traffic tunnel. J Air Waste Manag Assoc 1995 0.75
335 Properties of liver retinyl ester hydrolase in young pigs. Biochim Biophys Acta 1986 0.75
336 Memorial. Thomas Preston White. M.D. Trans Am Clin Climatol Assoc 1969 0.75
337 Raltegravir resistance in the cerebrospinal fluid. Infection 2013 0.75
338 Nasopharyngeal cyst simulating Kaposi's sarcoma in an HIV-infected patient. J Laryngol Otol 1990 0.75
339 Effect of the revised CDC case definition of AIDS on the number of AIDS cases in the Sydney AIDS Prospective Study. Aust N Z J Med 1992 0.75
340 HIV and malignancy. J Acquir Immune Defic Syndr 1993 0.75
341 Resection and survival in bronchogenic carcinoma. Prog Clin Cancer 1970 0.75